Randomized, placebo-controlled study of the effect of verapamil on exercise hemodynamics in coronary artery disease.
At cardiac catheterization, 16 patients with coronary artery disease (14 men and 2 women) were allocated by a random, double-blind method to intervention with placebo (saline solution) or verapamil (0.2 mg/kg total by bolus and by 10-minute infusion). In all patients, resting and exercise (3 minutes with a bicycle at 150 kg X m/min) hemodynamic values were obtained during a control period and after intervention. Subsequent left ventriculography and coronary arteriography revealed a mean ejection fraction of 52 and 53% and the mean number of diseased vessels (3-vessel scale) of 2.1 and 1.5 in the placebo and verapamil groups, respectively. In both groups of patients, exercise induced significant increased heart rate, mean arterial pressure, left ventricular end-diastolic pressure and cardiac index. Verapamil increased the heart rate and decreased the mean arterial pressure at rest and the arterial pressure during exercise. It did not affect exercise-induced increases in left ventricular end-diastolic pressure or cardiac index. These results support a role for peripheral mechanisms mediating the antianginal effects of verapamil.
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011897:Random Allocation; D013318:Stroke Volume / Q000187:drug effects; D014700:Verapamil / Q000627:therapeutic use*
D010919:Placebos; D014700:Verapamil